Surrogate end-points for treatment trials of hepatitis B virus.
Griffiths
P D
PD
D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis* / Q000097:blood; D004798:Enzymes / Q000097:blood; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D008099:Liver / Q000201:enzymology; D016032:Randomized Controlled Trials as Topic; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D015415:Biomarkers; D004798:Enzymes; D006513:Hepatitis B e Antigens